Solara Active Pharma Sciences Limited reported a 20% year-on-year rise in revenue to ₹384 crore for Q1 FY27, driven by strong performance in its base business despite headwinds from the West Asia crisis. The company achieved its highest EBITDA of ₹63.5 crore and net profit (PAT) of ₹16.3 crore in 18 quarters, with PAT surging 55% year-on-year. Management highlighted disciplined execution and working capital optimization as key drivers, while noting that the ibuprofen segment continues to face profitability challenges.

The earnings conference call, held on July 23, 2026, was conducted pursuant to Regulation 30 and Regulation 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript was uploaded to the company’s website and stock exchanges on July 29, 2026, by Pooja Jaya Kumar, Company Secretary and Compliance Officer (ICSI Membership No. A57415).

Financial Performance

Solara’s base business revenue reached ₹307 crore, up 24% year-on-year, contributing significantly to the overall growth. Gross margins for the base business stood at ₹158 crore, up 10% year-on-year, with an EBITDA of ₹72 crore, up 8% year-on-year. The consolidated EBITDA margin improved by 80 basis points quarter-on-quarter to 17%.

Balance Sheet and Debt Reduction

The company reduced its net debt by approximately ₹135 crore during the quarter, representing a 22% reduction. This deleveraging was supported by ₹100 crore from the final call money of the rights issue realized in May 2026 and ₹35 crore from operational cash flows. As of June 30, 2026, net debt stood at ₹479 crore, implying a net debt-to-EBITDA multiple of roughly 1.9x based on annualized Q1 EBITDA. Management indicated a line of sight to reduce debt to sub-₹450 crore, approximately ₹440 crore, by March 2027, which would improve the multiple to roughly 1.7x.

Operational Challenges and Strategic Review

The ibuprofen business continues to face profitability challenges, reporting an EBITDA margin of negative 12%. Management attributed this to a difficult operating environment driven by solvent shortages and geopolitical tensions in West Asia, which impacted raw material availability and pricing. Despite this, there was a marginal sequential improvement in the quarter. The company expects the ibuprofen segment to incur an EBITDA loss between ₹10 crore and ₹15 crore per quarter in the near term.

A strategic review of the ibuprofen business is ongoing, with management confirming it is on track to conclude by H1 FY27. No final decision has been made regarding the future of the unit, though management noted that recovering the entire deployed capital of approximately ₹700 crore may be challenging.

What the Numbers Show

The divergence between the robust growth in the base business and the persistent losses in the ibuprofen segment highlights Solara’s shifting focus toward higher-margin API products. While raw material cost pressures from the West Asia crisis have introduced volatility in gross margins, the company’s ability to pass through costs—accounting for roughly ₹30 crore of consolidated revenue growth—has protected absolute margin values. The aggressive debt reduction strategy, fueled by rights issue proceeds and operational cash flows, positions the company to become net-debt-free by FY29, assuming continued execution on debottlenecking capex projects aimed at enhancing capacity utilization across its Cuddalore, Bangalore, and Ambernath sites.

Solara Active Pharma Sciences reported a 60% year-on-year increase in consolidated profit after tax (PAT) to ₹163 million for the quarter ended June 30, 2026, driven by robust growth in its core Active Pharmaceutical Ingredient (API) business. Revenue from operations rose 20% to ₹3,816 million, while EBITDA grew 10% to ₹635 million. The Board of Directors approved the unaudited standalone and consolidated financial results on July 23, 2026, following a limited review by statutory auditors Deloitte Haskins & Sells LLP. Despite the quarterly profit, the group carries accumulated losses of ₹28,621 million as of June 30, 2026, though management maintains a going concern basis citing adequate working capital facilities and operational cash flows.

Financial Performance Highlights

The company’s strong performance was anchored by its base business, which excludes the commodity Ibuprofen segment. Base business revenues surged 24% to ₹3,077 million, up from ₹2,487 million in the corresponding period of the previous year. This growth offset profitability challenges in the Ibuprofen business, which reported an EBITDA loss of ₹87 million on revenues of ₹765 million. Management is evaluating strategic options for the Ibuprofen unit and expects to finalize next steps by the end of Q2FY27. Consequently, the previously approved demerger of the CRAMS and Polymers business has been placed on hold.

Balance Sheet and Rights Issue Utilization

Solara Active Pharma Sciences significantly improved its balance sheet position, reducing net debt by ₹1,346 million during the quarter to ₹4,795 million. This reduction was achieved through the repayment of ₹1,000 million from rights issue proceeds and ₹346 million from operational cash flows. As of June 30, 2026, the company had raised ₹44,273 million out of the total rights issue size of ₹44,995 million. The proceeds comprise ₹15,748 million received as application money, ₹15,531 million against the first call made on May 6, 2025, and ₹12,994 million against the final call made on May 7, 2026. The unutilized balance is held in bank accounts pending deployment.

The net worth improved to ₹10,419 million as of June 30, 2026, up from ₹8,880 million in March 2026. Management projects net debt to reach approximately ₹4,406 million by March 2027, targeting a net debt-to-EBITDA ratio of around 1.7 times.

What the Numbers Show

The divergence between the base business and the Ibuprofen segment highlights the structural shift in Solara’s revenue mix. While the base business delivered a healthy 23.5% EBITDA margin, supported by regulated markets contributing over 75% of revenues, the Ibuprofen segment continues to drag on overall profitability. The substantial reduction in net debt, coupled with the near-complete closure of the rights issue, provides the company with a stronger liquidity buffer to navigate input cost pressures from geopolitical developments in West Asia. However, the persistent accumulated losses of over ₹28,000 million underscore the long-term capital intensity of the business model, making the successful execution of strategic options for the Ibuprofen unit critical for future margin expansion.